POST LEONARD E sold $350K of CGON
POST LEONARD E sold 5,000 shares of CG Oncology, Inc. (CGON) at $70.00 ($0.35M total) on 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s open-market sale of 5,000 shares for $350,000 is disclosed, with holdings reduced to 0 shares after the transaction.
Market read
Traders may note the insider sale, but the 10b5-1 structure and lack of new operating/clinical/regulatory information limit impact.
What to watch
The sale is explicitly under a pre-arranged 10b5-1 plan; without additional context (e.g., concurrent buys, material events), it’s usually not a tradable fundamental catalyst.
Background
The article is an SEC Form 4 insider transaction disclosure for CG Oncology, Inc.
Ticker impact
SEC Form 4 shows director POST LEONARD E sold 5,000 CG Oncology shares on 2026-06-24 for $350,000 under a 10b5-1 plan.
Low near-term impact; any effect would be sentiment-only and likely short-lived.
The filing is a scheduled open-market sale by a director with a pre-arranged 10b5-1 plan and no accompanying fundamental catalyst.
Market effects
No sector read-across; single-company insider transaction without new clinical/regulatory data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, a director fully exiting (0 shares after sale) can still be viewed as a mild negative sentiment signal by some traders.
Key entities
- issuerCG Oncology, Inc.
Company whose director insider sale is disclosed on Form 4.
- insiderPOST LEONARD E
Director who sold 5,000 shares on 2026-06-24 under a 10b5-1 plan.